Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives
The tumor necrosis factor superfamily (TNFSF) and their receptors (TNFRSF) are important regulators of the immune system, mediating proliferation, survival, differentiation, and function of immune cells. As a result, their targeting for immunotherapy is attractive, although to date, under-exploited....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1147467/full |
| _version_ | 1797839949907623936 |
|---|---|
| author | Osman Dadas Ayse Ertay Mark S. Cragg Mark S. Cragg |
| author_facet | Osman Dadas Ayse Ertay Mark S. Cragg Mark S. Cragg |
| author_sort | Osman Dadas |
| collection | DOAJ |
| description | The tumor necrosis factor superfamily (TNFSF) and their receptors (TNFRSF) are important regulators of the immune system, mediating proliferation, survival, differentiation, and function of immune cells. As a result, their targeting for immunotherapy is attractive, although to date, under-exploited. In this review we discuss the importance of co-stimulatory members of the TNFRSF in optimal immune response generation, the rationale behind targeting these receptors for immunotherapy, the success of targeting them in pre-clinical studies and the challenges in translating this success into the clinic. The efficacy and limitations of the currently available agents are discussed alongside the development of next generation immunostimulatory agents designed to overcome current issues, and capitalize on this receptor class to deliver potent, durable and safe drugs for patients. |
| first_indexed | 2024-04-09T16:06:29Z |
| format | Article |
| id | doaj.art-8b5755ed18974dd39aa3959d301a8ad5 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T16:06:29Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8b5755ed18974dd39aa3959d301a8ad52023-04-25T05:51:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-04-011410.3389/fimmu.2023.11474671147467Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectivesOsman Dadas0Ayse Ertay1Mark S. Cragg2Mark S. Cragg3Antibody and Vaccine Group, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United KingdomSchool of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United KingdomAntibody and Vaccine Group, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United KingdomInstitute for Life Sciences, University of Southampton, Southampton, United KingdomThe tumor necrosis factor superfamily (TNFSF) and their receptors (TNFRSF) are important regulators of the immune system, mediating proliferation, survival, differentiation, and function of immune cells. As a result, their targeting for immunotherapy is attractive, although to date, under-exploited. In this review we discuss the importance of co-stimulatory members of the TNFRSF in optimal immune response generation, the rationale behind targeting these receptors for immunotherapy, the success of targeting them in pre-clinical studies and the challenges in translating this success into the clinic. The efficacy and limitations of the currently available agents are discussed alongside the development of next generation immunostimulatory agents designed to overcome current issues, and capitalize on this receptor class to deliver potent, durable and safe drugs for patients.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1147467/fullTNFRagonismco-stimulationcancerimmunotherapy |
| spellingShingle | Osman Dadas Ayse Ertay Mark S. Cragg Mark S. Cragg Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives Frontiers in Immunology TNFR agonism co-stimulation cancer immunotherapy |
| title | Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives |
| title_full | Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives |
| title_fullStr | Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives |
| title_full_unstemmed | Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives |
| title_short | Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives |
| title_sort | delivering co stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy past current and future perspectives |
| topic | TNFR agonism co-stimulation cancer immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1147467/full |
| work_keys_str_mv | AT osmandadas deliveringcostimulatorytumornecrosisfactorreceptoragonismforcancerimmunotherapypastcurrentandfutureperspectives AT ayseertay deliveringcostimulatorytumornecrosisfactorreceptoragonismforcancerimmunotherapypastcurrentandfutureperspectives AT markscragg deliveringcostimulatorytumornecrosisfactorreceptoragonismforcancerimmunotherapypastcurrentandfutureperspectives AT markscragg deliveringcostimulatorytumornecrosisfactorreceptoragonismforcancerimmunotherapypastcurrentandfutureperspectives |